Skip to content

Effects of Oxytocin on Reinforcement Learning and Interoception

The Modulatory Effects of Oxytocin on Reinforcement Learning and Interoceptive Processing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05245708
Enrollment
80
Registered
2022-02-18
Start date
2021-04-15
Completion date
2021-12-15
Last updated
2024-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

oxytocin, learning, interoception

Brief summary

The main aim of the study is to investigate whether intranasal oxytocin has effects on reinforcement learning under dynamic environment and interoceptive processing based on behavioral and electroencephalogram (EEG) responses.

Detailed description

A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. (1) Participants first complete a probabilistic reward learning task 45 minutes after treatment with behavioral (response time and accuracy) and EEG data (ERP components such as FRN, ERN and P300) being collected during this task. (2) A resting-state recording and a heartbeat counting task are conducted following the learning task with ECG and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), the Cognitive Flexibility Inventory(CFI), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the tasks.

Interventions

DRUGIntranasal oxytocin

Each subject will be assigned to intranasal administration of oxytocin (24 IU).

DRUGintranasal placebo

Each subject will be assigned to intranasal placebo.

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 28 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects without any past or present psychiatric or neurological disorders.

Exclusion criteria

* History of brain injury medical or mental illness.

Design outcomes

Primary

MeasureTime frameDescription
Behavioral index in the learning task: chioce accuracy45-65 minutes after treatment administrationThe accuracy of subjects choosing the better option.
Behavioral index in the heartbeat counting task: interoceptive accuracy65-75 minutes after treatment administrationIndividuals' ability to perceive internal cardiac signals

Secondary

MeasureTime frameDescription
ERP components in the learning task: ERN, FRN, P300, N2pc45-65 minutes after treatment administrationERN and FRN are indices of reward expectancy and prediction error in reinforcement learning. P300 is associated with attention allocation. N2pc is an early component associated with visual selective attention.
ERP components in the heartbeat counting task: heartbeat-evoked potential (HEP)65-75 minutes after treatment administrationHEP is a scalp event-related potential that reflects cortical processing of cardiac interoceptive signals

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026